Shilpa Medicare Limited announced its consolidated unaudited financial results for the quarter and half-year ended September 30, 2025. The pharmaceutical and biotechnology company with 16 subsidiaries across India, Europe, the USA and Asia demonstrated exceptional profitability growth driven by a strong product mix, operational efficiencies and robust order execution across its oncology, immunology, diabetes and infectious diseases portfolio.
For the quarter ended September 30, 2025, Shilpa Medicare achieved consolidated revenue from operations of ₹369.97 crore, registering growth of 8% YoY and 15% QoQ. Total income stood at ₹371.72 crore, up 7% YoY and 13% QoQ compared to the respective periods.
Profit before tax reached ₹64.43 crore, marking an exceptional expansion of 75% YoY and 30% QoQ. Profit after tax stood at ₹44.07 crore, demonstrating outstanding growth of 146% YoY, though declining 6% QoQ. Basic and diluted earnings per share were ₹2.25 for the quarter compared to ₹0.92 in Q2 FY25.
For the half year ended September 30, 2025, consolidated revenue from operations reached ₹691.43 crore, up 9% from ₹636.31 crore in H1 FY25. Total income totalled ₹699.56 crore, reflecting 7% growth year on year.
Half-year PBT stood at ₹114.01 crore, surging 74% from ₹65.45 crore previously. PAT came to ₹90.95 crore, up 184% from ₹32 crore in H1 FY25. Earnings per share for the half year were ₹4.65, up 182% YoY, demonstrating dramatic profitability improvement.
Read More: Cipla, Natco Pharma, and Other Firms Win Several Drug Supply Bids in China!
The company demonstrated remarkable margin expansion with PAT margin improving to 11.9% in Q2 FY26 from 5.2% in Q2 FY25, reflecting 470 basis points improvement. For H1 FY26, PAT margin reached 13.2% versus 5% in H1 FY25, showcasing operational excellence and a favourable product portfolio mix. The profitability surge was driven by higher value-added products and improved asset utilisation.
The consolidated results include 16 subsidiaries spanning pharmaceutical manufacturing and healthcare: Shilpa Pharma Lifesciences, Shilpa Therapeutics, Shilpa Biologicals, Shilpa Biocare, FTF Pharma, Vegil Labs, Makindus Inc USA, Shilpa Pharma Inc USA, Pilnova Pharma Inc USA, Koanaa Healthcare entities in the UK, Austria, Canada, Spain, Koanna International Dubai, Indo Biotech Malaysia and Shilpa Lifesciences as a step-down subsidiary.
The group includes 4 joint ventures: Reva Medicare, Sravathi Advance Process Technologies, Sravathi AI Technologies and Oncosol Limited. The group has 1 associate: MAIA Pharmaceuticals Inc., USA, focused on novel cancer therapeutics.
Cost of materials consumed stood at ₹127.64 crore in Q2 FY26, while employee benefits expense was ₹83.05 crore. Finance costs remained at ₹15.66 crore. Depreciation and amortisation expenses totalled ₹29.82 crore. The company maintained disciplined cost management while scaling operations and product launches.
The company continues to focus on oncology, immunology, diabetes and infectious diseases with both generic API manufacturing and biosimilar development capabilities. The extensive subsidiary network across regulated markets positions Shilpa Medicare for sustained growth as pipeline products achieve commercialisation milestones and regulatory approvals in key geographies.
On November 13, 2025, Shilpa Medicare share price opened at ₹407.00 on NSE, above the previous close of ₹399.90. During the day, it surged to ₹415.00 and dipped to ₹388.35. The stock is trading at ₹391.00 as of 3:18 PM. The stock registered a significant decline of 2.23%.
Over the past week, it has moved up by 6.09%, over the past month, it has moved up by 9.63%, and over the past 3 months, it has declined by 13.60%.
Shilpa Medicare demonstrated exceptional consolidated turnaround in Q2 and H1 FY26 with PAT surging 146% YoY to ₹44.07 crore and revenue growing 8% YoY to ₹369.97 crore, powered by dramatic margin expansion to 11.9% from 5.2%, strong product mix optimisation, operational efficiencies and robust order execution across its expansive 16 subsidiary global pharmaceutical manufacturing and biotechnology ecosystem spanning India, USA, Europe and Asia.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Nov 13, 2025, 5:21 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
